PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
59.63%
Net income growth above 1.5x VET's 17.47%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-1.23%
Both reduce yoy D&A, with VET at -11.63%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
71.43%
Well above VET's 110.87% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
-76.76%
Negative yoy working capital usage while VET is 138.31%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
-283.33%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-76.76%
Negative yoy usage while VET is 138.31%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
181.25%
Some yoy increase while VET is negative at -76.58%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
45.84%
Operating cash flow growth similar to VET's 44.06%. Walter Schloss would see parallel improvements or market conditions in cash generation.
2.28%
Some CapEx rise while VET is negative at -91.17%. John Neff would see competitor possibly building capacity while we hold back expansions.
-47.37%
Negative yoy acquisition while VET stands at 28.26%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
-100.00%
Negative yoy purchasing while VET stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
-100.00%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
64.67%
Less 'other investing' outflow yoy vs. VET's 473.43%. David Dodd would see a stronger short-term cash position unless competitor invests more wisely.
-82.45%
Both yoy lines negative, with VET at -21.02%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
69.83%
We repay more while VET is negative at -1.04%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.